Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Two Patent Applications Related to RNAi: Oct 18, 2007

Title: RNA Interference Pathway Genes as Tools for Targeted Genetic Interference
Number: 7,282,564
Filed: Aug. 20, 2003
Lead Inventor: Craig Mello, University of Massachusetts Medical School
“Genes involved in double-stranded RNA interference are identified and used to investigate the RNAi pathway,” the patent’s abstract states. “The genes and their products are also useful for modulating RNAi pathway activity.”

Title: Polynucleotides for Reducing Respiratory Syncytial Virus Gene Expression
Number: 20070238676 
Filed: Dec. 6, 2004 PCT Filed: Dec. 6, 2004
Lead Inventor: Shyam Mohapatra, University of South Florida
According to the patent application’s abstract, “this invention pertains to polynucleotides, such as small interfering RNA, useful for reducing the expression of respiratory syncytial virus genes within a subject; and methods for treating a patient suffering from, or at risk of developing, an RSV infection by administering such polynucleotides to the subject.”

Title: siRNA Targeting Chemokine Receptor 4
Number: 20070238868
Filed: April 3, 2007
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CXCR4.”

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.